O4 Hubs detail
O4 Detail Hero Banner

Drug Pipeline Insights Report

3 new drugs to watch this fall

Are these new gene therapies worth the price?​

By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: October 2022

O4 1 Column (Full)
O4 Text Component

Welcome to the fall edition of Drugs to Watch.

O4 2 Columns (2/3 - 1/3)
O4 1 Column (Full)
O4 Text Component

As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision this fall.

Two of the three drugs discussed have an Orphan Drug designation while the third was granted Priority Review. In today's market, we are seeing new orphan drugs more frequently and expect this trend to continue. However, you may be surprised by the price tag.

The drugs in this report include treatments for:

  • Kidney disease
  • Inherited bleeding disorder
  • Eye disease

View report

Don't want to read the full report? Download the brief summary.

View summary

Related content

O4 Complex Card

How a client avoided $109M in pharmacy costs

New case study shows effectiveness of drug management program.
O4 Complex Card

4 more psoriasis drugs on the way

Psoriasis costs up 40% in 5 years. Will these drugs help?
O4 Complex Card

5 questions: Optum Rx chief pharmacy officer

Michael Einodshofer addresses the risks, challenges and opportunities facing the industry.